MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598905 | Name: Sultopride free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sultopride is a selective D2 and D3 receptor antagonist. Sultopride was 4-6 times as potent as sulpiride in stimulating prolactin secretion. Sultopride neutralized the dopamine-mediated inhibition of prolactin secretion from the anterior pituitary in vitro. sultopride, like sulpiride, stimulates prolactin secretion by blocking the dopamine receptor in the pituitary.

Chemical Structure

Sultopride free base
Sultopride free base
CAS#53583-79-2 (free base)

Theoretical Analysis

MedKoo Cat#: 598905

Name: Sultopride free base

CAS#: 53583-79-2 (free base)

Chemical Formula: C17H26N2O4S

Exact Mass: 354.1613

Molecular Weight: 354.46

Elemental Analysis: C, 57.60; H, 7.39; N, 7.90; O, 18.05; S, 9.04

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
23694-17-9 (HCl) 53583-79-2 (free base)
Synonym
Sultopride; LIN 1418; LIN-1418; LIN1418; LIN 1418; Sultopridum;
IUPAC/Chemical Name
N-((1-ethylpyrrolidin-2-yl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide
InChi Key
UNRHXEPDKXPRTM-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H26N2O4S/c1-4-19-10-6-7-13(19)12-18-17(20)15-11-14(24(21,22)5-2)8-9-16(15)23-3/h8-9,11,13H,4-7,10,12H2,1-3H3,(H,18,20)
SMILES Code
O=C(NCC1N(CC)CCC1)C2=CC(S(=O)(CC)=O)=CC=C2OC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 354.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Silvestre FJ, Silvestre-Rangil J, López-Jornet P. Burning mouth syndrome: a review and update. Rev Neurol. 2015 May 16;60(10):457-63. Review. English, Spanish. PubMed PMID: 25952601. 2: Mizuchi A, Kitagawa N, Miyachi Y. Regional distribution of sultopride and sulpiride in rat brain measured by radioimmunoassay. Psychopharmacology (Berl). 1983;81(3):195-8. PubMed PMID: 6417707. 3: Mizuchi A, Kitagawa N, Saruta S, Tokuda H, Miyachi Y. Effect of sultopride on prolactin secretion in rats. Arch Int Pharmacodyn Ther. 1984 Feb;267(2):232-40. PubMed PMID: 6424592. 4: Kamizono A, Inotsume N, Fukushima S, Nakano M. Disposition of enantiomers of sultopride in a human, rats and rabbits. Biol Pharm Bull. 1993 Nov;16(11):1121-3. PubMed PMID: 7906175. 5: Miyachi Y, Mizuchi A, Hamano H, Sarai K. Effects of chronic sultopride treatment on endocrine systems in psychotic women. Psychopharmacology (Berl). 1984;82(4):287-90. PubMed PMID: 6427815. 6: Kobari T, Iguro Y, Ito T, Namekawa H, Kato Y, Yamada S. Absorption, distribution and excretion of sultopride in man and several animal species. Xenobiotica. 1985 Jul;15(7):605-13. PubMed PMID: 4049901. 7: Kobari T, Namekawa H, Kato Y, Yamada S. Biotransformation of sultopride in man and several animal species. Xenobiotica. 1985 Jun;15(6):469-76. PubMed PMID: 4036171. 8: Bressolle F, Bres J. [Determination of sulpiride and sultopride by high-performance liquid chromatography for pharmacokinetic studies]. J Chromatogr. 1985 Jun 14;341(2):391-9. French. PubMed PMID: 4030988. 9: Kamizono A, Inotsume N, Fukushima S, Nakano M, Okamoto Y. Inhibitory effects of procainamide and probenecid on renal excretion of sultopride enantiomers in rats. J Pharm Sci. 1993 Dec;82(12):1259-61. PubMed PMID: 8308707. 10: Moriuchi K, Imazu Y, Yoneda H. Differences in effects of sultopride and sulpiride on dopamine turnover in rat brain. Neurochem Res. 1995 Jan;20(1):95-9. PubMed PMID: 7739765. 11: Mizuchi A, Kitagawa N, Saruta S, Miyachi Y. Characteristics of [3H]sultopride binding to rat brain. Eur J Pharmacol. 1982 Oct 15;84(1-2):51-9. PubMed PMID: 6128237. 12: Mizuchi A, Saruta S, Kitagawa N, Miyachi Y. Development of radioimmunoassay for sultopride and sulpiride. Arch Int Pharmacodyn Ther. 1981 Dec;254(2):317-26. PubMed PMID: 7337503. 13: Lande G, Drouin E, Gauthier C, Chevallier JC, Godin JF, Chiffoleau A, Le Marec H. [Arrhythmogenic effects of sultopride chlorhydrate: clinical and cellular electrophysiological correlation]. Ann Fr Anesth Reanim. 1992;11(6):629-35. French. PubMed PMID: 1363741. 14: Jitsufuchi N, Kudo K, Tokunaga H, Imamura T. Selective determination of sultopride in human plasma using high-performance liquid chromatography with ultraviolet detection and particle beam mass spectrometry. J Chromatogr B Biomed Sci Appl. 1997 Mar 7;690(1-2):153-9. PubMed PMID: 9106039. 15: Dugas M, Le Heuzey MF. [Use of sultopride in child and adolescent psychiatry]. Neuropsychiatr Enfance Adolesc. 1984 Oct-Nov;32(10-11):557-62. French. PubMed PMID: 6395036. 16: Horikomi K, Fujita M. [Comparative study of the pharmacological properties of sultopride sulpiride and other antipsychotic drugs: influence of sultopride, sulpiride and other antipsychotic drugs on spontaneous locomotor activity and changes in locomotor activity induced by apomorphine and clonidine in mice]. Yakubutsu Seishin Kodo. 1986 Sep;6(3):339-52. Japanese. PubMed PMID: 2880435. 17: Someya T, Shimoda K, Muratake T, Nakajima E, Shirai A, Funaoka H, Yashiki T, Ishii H, Sunahara N, Takahashi S. Establishment of enzyme immunoassay for measuring serum sultopride levels. Ther Drug Monit. 2001 Jun;23(3):277-81. PubMed PMID: 11360038. 18: Gadisseux JF, Fournaux J, Hallet J, Ferriere G. [Sultopride, treatment of choice for psychomotor agitation in severe encephalopathy. 33 cases in a neuropediatric milieu]. Acta Neurol Belg. 1982 Nov-Dec;82(6):327-38. French. PubMed PMID: 7164767. 19: Mohy Y. [Sultopride in the treatment of agitation]. Sem Hop. 1983 Apr 28;59(17):1327-30. French. PubMed PMID: 6306814. 20: Montaz L, Varache N, Harry P, Aymes C, Turcant A, Delille F, Simonin D, Hass C. [Torsades de pointes during sultopride poisoning]. J Toxicol Clin Exp. 1992 Dec;12(8):481-6. French. PubMed PMID: 1364061.